Blood Cancer Journal - Table of Contents alert Volume 5 August 2015

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 5, August 2015 In this issue Review Original Articles Letters to the Editor Sign up for e-alerts Web feed Advertisement Blood Cancer Journal is an online-only, open access journal, publishing high quality research on hematologic malignancies and related disorders. Explore the benefits of submitting your next research article. Review Top Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis T Barbui, J Thiele, A M Vannucchi and A Tefferi Blood Cancer J 2015 5: e337; 10.1038/bcj.2015.64 Abstract | Full Text Original Articles Top Favorable clinical outcome and unique characteristics in association with Twist1 overexpression in de novo acute myeloid leukemia C-C Chen, J-Y You, J-P Gau, C-E Huang, Y-Y Chen, Y-H Tsai, H-J Chou, J Lung and M-H Yang Blood Cancer J 2015 5: e339; 10.1038/bcj.2015.67 Abstract | Full Text Prognostic signature and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemia A M Hurtado, T-H Chen-Liang, B Przychodzen, C Hamedi, J Muñoz-Ballester, B Dienes, M D García-Malo, A I Antón, F de Arriba, R Teruel-Montoya, F J Ortuño, V Vicente, J P Maciejewski and A Jerez Blood Cancer J 2015 5: e342; 10.1038/bcj.2015.65 Abstract | Full Text Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length Y Kim, G D Lee, J Park, J-H Yoon, H-J Kim, W-S Min and M Kim Blood Cancer J 2015 5: e336; 10.1038/bcj.2015.61 Abstract | Full Text Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib S K Kumar, B LaPlant, V Roy, C B Reeder, M Q Lacy, M A Gertz, K Laumann, M A Thompson, T E Witzig, F K Buadi, C E Rivera, J R Mikhael, P L Bergsagel, P Kapoor, L Hwa, R Fonseca, A K Stewart, A Chanan-Khan, S V Rajkumar and A Dispenzieri Blood Cancer J 2015 5: e338; 10.1038/bcj.2015.60 Abstract | Full Text T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330 G S Laszlo, C J Gudgeon, K H Harrington and R B Walter Blood Cancer J 2015 5: e340; 10.1038/bcj.2015.68 Abstract | Full Text Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma A J Novak, Y W Asmann, M J Maurer, C Wang, S L Slager, L S Hodge, M Manske, T Price-Troska, Z-Z Yang, M T Zimmermann, G S Nowakowski, S M Ansell, T E Witzig, E McPhail, R Ketterling, A L Feldman, A Dogan, B K Link, T M Habermann and J R Cerhan Blood Cancer J 2015 5: e346; 10.1038/bcj.2015.69 Abstract | Full Text A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis A Pardanani, A Tefferi, C Jamieson, N Y Gabrail, C Lebedinsky, G Gao, F Liu, C Xu, H Cao and M Talpaz Blood Cancer J 2015 5: e335; 10.1038/bcj.2015.63 Abstract | Full Text Factors associated with an increased risk of vertebral fracture in monoclonal gammopathies of undetermined significance J M Piot, M Royer, A Schmidt-Tanguy, E Hoppé, M Gardembas, T Bourrée, M Hunault, S François, F Boyer, N Ifrah, G Renier, A Chevailler, M Audran, D Chappard, H Libouban, G Mabilleau, E Legrand and B Bouvard Blood Cancer J 2015 5: e345; 10.1038/bcj.2015.71 Abstract | Full Text Letters to the Editor Top Does day 11 omission of methotrexate due to toxicity influence the outcome in myeloablative hematopoietic cell transplant? Results from a single-center retrospective cohort study B K Hamilton, L Rybicki, H Haddad, D Abounader, M Yurch, N S Majhail, R Hanna, R Sobecks, R Dean, H Liu, B Hill, E Copelan, B Bolwell and M Kalaycio Blood Cancer J 2015 5: e344; 10.1038/bcj.2015.70 Full Text Brentuximab vedotin: axonal microtubule’s Apollyon S Mariotto, S Ferrari, M Sorio, F Benedetti, G Tridente, T Cavallaro, A Gajofatto and S Monaco Blood Cancer J 2015 5: e343; 10.1038/bcj.2015.72 Full Text Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211 S Z Usmani, R Sexton, S Ailawadhi, J J Shah, J Valent, M Rosenzweig, B Lipe, J A Zonder, S Fredette, B Durie, A Hoering, B Bartlett and R Z Orlowski Blood Cancer J 2015 5: e334; 10.1038/bcj.2015.62 Full Text Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma L Vincent, P Ceballos, C Plassot, J C Méniane, P Quittet, R Navarro, C Cyteval, V Szablewski, Z Y Lu, T Kanouni, J Moreaux, G Cartron, B Klein and N Fegueux Blood Cancer J 2015 5: e341; 10.1038/bcj.2015.48 Full Text Advertisement Nature Publishing Group offers a free open access funding support service to enable authors to discover and apply for article processing charge funding available to them. Visit our website for further advice on the funding options available, and guidance in approaching funders and institutions, or email openaccess@nature.com for more information.  You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.